Drugs Made In America Acquisition Corp. (DMAAR) — 10-Q Filings
All 10-Q filings from Drugs Made In America Acquisition Corp.. Browse 3 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (3)
-
DMAAR Swings to Profit on Trust Account Interest, Hunts Pharma Target
— Nov 18, 2025 Risk: medium
Drugs Made In America Acquisition Corp. (DMAAR) reported a net income of $5,727,685 for the nine months ended September 30, 2025, a significant turnaround from -
Drugs Made In America Acquisition Corp. Files Q2 2025 10-Q
— Aug 14, 2025 Risk: low
Drugs Made In America Acquisition Corp. filed its quarterly report for the period ended June 30, 2025. The company, incorporated in the Cayman Islands, is headq -
Drugs Made In America Acquisition Corp. Files Q1 2025 10-Q
— May 20, 2025 Risk: low
Drugs Made In America Acquisition Corp. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in the Cayman Isl
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX